Peregrine shares continue roller coaster ride on revised cancer data; Chiesi bids for remaining Cornerstone shares;

 @FierceBiotech: If you missed it yesterday, check out @RyanMFierce's feature on FierceBiotechIT.com: Top 10 Biotech Techies, 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Interesting biotech model: NC development team nabs $5M angel tranche for their latest biotech play. Story | Follow @JohnCFierce

> Shares of Peregrine Pharmaceuticals ($PPHM) continued on a roller-coaster ride yesterday after the biotech disappointed investors with a revised look at midstage lung cancer data for bavituximab. Peregrine has been trying to repair the damage inflicted by its announcement 5 months ago that there were major discrepancies in their data. A few weeks ago the company said that the discrepancies were limited to the placebo and the 1 mg/kg treatment arms. Story

> Chiesi Farmaceutici SpA is making a bid to buy the 40% of Cornerstone Therapeutics ($CRTX) shares it doesn't already own. Release

> Curis has lured ACT Biotech founder Ali Fattaey into a new job as president and COO. Report

> Selexis SA announced today that Amgen ($AMGN) has expanded their R&D license agreement to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line for research and development. Release

Pharma News

@FiercePharma: Chinese government plans to cut the number of drug wholesalers to 3K from 13K. Pharma stocks there rose on the news. More | Follow @FiercePharma

@EricPFierce: Gilead, Teva now making nice over Viread patent, ending years of litigation. News | Follow @EricPFierce

@AlisonBFierce: HealthMap has expanded its reach, allowing people to search for any of 11 vaccines available near their home. Story | Follow @AlisonBFierce

> Gilead, Teva wrap up Viread patent fight. News

> Italian antitrust agency probes alleged Roche-Novartis cartel. Report

> Study: ED drugmakers aren't properly policing their TV ads. Story

Medical Device News

 @FierceMedDev: Dune gains CE mark for next-gen breast cancer Dx tool. News | Follow @FierceMedDev

 @MarkHFierce: Hmm, the second med device venture funding in two days. This time, a focus on uterine fibroid ablation. Release | Follow @MarkHFierce

 @DamianFierce: Thanks to investor excitement, Life Technologies might now be too pricey for a sale. More | Follow @DamianFierce

> Natera launches prenatal diagnostic with big Quest co-sign. Story

> Medtronic halves estimate of device tax hit. Item

Drug Delivery News

> Lentigen's stem-cell delivery for brain tumors nets FDA orphan status. News

> PolyActiva seeks drug partner for new intraocular delivery implant. Report

> Oramed presses forward into PhII with oral insulin pill. Story

> EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand. Item

Biomarkers News

> NIH pours $900K into Parkinson's biomarker research. News

> Alzheimer's biomarkers indicate dementia advancement. More

> Mayo study spotlights new biomarkers for quick kidney injury alert. Report

> NYU investigative team on the trail of PTSD biomarkers. Article

> Nanomix plans test of triple biomarker heart attack Dx. Story

And Finally… Researchers from Göttingen and Bonn have shed new light on the chemical compound known as "methylene blue," a possible drug candidate for Alzheimer's. Release

 

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.